Introduction {#cesec10}
============

Osteoarthritis is the most common form of arthritis worldwide, affecting about 40% of people older than 70 years.[@bib1] It is a complex disease of the musculoskeletal system with both genetic and environmental risk factors.[@bib2] From the results of heritability studies in twins, sibling pairs, and families, genetic factors are estimated to account for about 50% of the risk of developing osteoarthritis in the hip or knee, although precise estimates vary according to sex, affected site, and severity of disease.[@bib3; @bib4] Despite extensive efforts, only three loci (*GDF5*, chromosome 7q22, and *MCF2L*)[@bib5; @bib6; @bib7; @bib8; @bib9; @bib10; @bib11] have thus far been associated with osteoarthritis at genome-wide significance levels (p≤5·0×10^−8^) in European populations. This lack of success in osteoarthritis might be attributed to several factors such as insufficient sample sizes in previous studies and disease heterogeneity that might result from different underlying causes, both genetic and environmental, depending on which joints are affected.[@bib4] The three established osteoarthritis loci have fairly small effect sizes (allele-wise odds ratios \[OR\] of about 1·15) and we have previously shown that the genetic basis of osteoarthritis is likely to consist of several signals of similar or smaller magnitude that necessitate large sample sizes for their detection at genome-wide significance levels.[@bib12] Phenotype definition in cases and controls is also a likely factor contributing to the dilution of power to detect strong signals. Improved definition of phenotype and reduced misclassification in such a prevalent disorder can enhance power.

To identify additional loci that confer susceptibility to osteoarthritis, we undertook a large well powered genome-wide association study (GWAS) of osteoarthritis within the context of the Arthritis Research UK Osteoarthritis Genetics (arcOGEN) Consortium. In 2011, we reported the results of an interim analysis of 43·8% of the full GWAS sample size, detecting no novel loci for osteoarthritis, but showing the polygenic nature of the disease\'s underlying genetics.[@bib12] Here, we report the results of the full-scale arcOGEN GWAS.

Methods {#cesec20}
=======

Study population {#cesec30}
----------------

We undertook a large case--control genome-wide association study (GWAS) in which 7410 unrelated patients were retrospectively and prospectively selected from hospitals and clinics, with about 80% of patients ascertained for the severe endpoint of total joint replacement \[TJR\]), and publicly available data were obtained from 11 009 unrelated controls from the UK\'s Wellcome Trust Case Control Consortium 2 (WTCCC2), Avon Longitudinal Study of Parents and Children, Type 1 Diabetes Genetics Consortium, and People of the British Isles studies ([table 1](#tbl1){ref-type="table"}; [appendix p 2](#sec1){ref-type="sec"}). We replicated the most promising signals in an independent set of up to 7473 cases and 42 938 controls from studies in Iceland (deCODE), Estonia (Estonian Genome Centre of University of Tartu \[EGCUT\]), the Netherlands (Genetics OsteoArthritis and Progression \[GARP\], Rotterdam study RSI and RSII cohorts), and the UK (TwinsUK). All patients and controls were of European descent. For further details, see [appendix pp 4--5](#sec1){ref-type="sec"}.

Procedures {#cesec40}
----------

The arcOGEN samples were genotyped by use of Illumina Human 610-Quad BeadChips (Illumina, San Diego, CA, USA; [appendix p 2](#sec1){ref-type="sec"}). Most cases had primary osteoarthritis requiring joint replacement of the hip or knee ([table 1](#tbl1){ref-type="table"}). We did quality-control checks both at the sample and single nucleotide polymorphism (SNP) levels ([appendix p 2](#sec1){ref-type="sec"}). We did a case--control analysis for an overlapping set of 485 491 autosomal SNPs in 7410 arcOGEN cases of osteoarthritis and 11 009 controls ([table 1](#tbl1){ref-type="table"}; [appendix p 2, p 73](#sec1){ref-type="sec"}). We imputed genotypes for autosomal SNPs by use of the directly typed data and phased genotype data from all HapMap III populations but did not see any additional signals (p\<10^−5^) arising from imputed SNPs that were not captured by the directly genotyped SNP analyses ([appendix p 3, p 6](#sec1){ref-type="sec"}). To assess the effect of phenotype misclassification in controls, we also analysed genome-wide genotypes in 4476 female cases of osteoarthritis from arcOGEN compared with 1828 osteoarthritis-free female controls from the TwinsUK dataset. We used a multiplicative model for the analysis of all data and also stratified by site of osteoarthritis, sex, and osteoarthritis severity---ie, only cases with TJR were assessed (for a total of 24 specific phenotypes). We have presented the results for all analyses in the [appendix pp 81--98](#sec1){ref-type="sec"}, and for the most significant specific phenotype in the main text. 129 prioritised SNPs (p\<10^−5^) were followed up by in-silico replication in the studies deCODE, EGCUT, GARP, Rotterdam study RSI and RSII cohorts, and TwinsUK (total in-silico replication sample size of 5064 cases of osteoarthritis and 40 619 controls). We subsequently undertook a de-novo replication of the 26 most significant SNPs in an additional independent set of 2409 arcOGEN cases of osteoarthritis and 2319 WTCCC2 population-based controls (UK replication). For our primary analysis, we used a meta-analysis framework to combine results for all data (discovery and replication) by use of a fixed-effects model ([appendix p 5](#sec1){ref-type="sec"}).

We used RT-PCR to assess the expression of at least one gene per signal in joint tissues from patients with osteoarthritis who were undergoing TJR, and in cartilage from individuals without clinical osteoarthritis. We investigated the expression patterns of nucleostemin, encoded by the *GNL3* gene, through immunohistochemical staining of normal and osteoarthritic cartilage samples and analysed protein expression in cultured chondrocytes from samples of normal and osteoarthritic cartilage by use of western blotting. Full details are available in the [appendix (p 6)](#sec1){ref-type="sec"}.

Statistical analysis {#cesec50}
--------------------

Statistical and imputational methods and Hardy-Weinberg equilibrium are described in the [appendix pp 2--5](#sec1){ref-type="sec"}.

Role of the funding source {#cesec60}
--------------------------

The sponsors of the study had no role in the study design, data collection, analysis or interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results {#cesec70}
=======

Genome-wide analysis showed an excess of signals compared with the null expectation of no association (genomic control inflation factor λ~1000~=1·009; [appendix p 74](#sec1){ref-type="sec"}). In the main analysis (all cases of osteoarthritis *vs* population-based controls), 28 SNPs (representing 12 independent signals) had a p value of less than 1·0×10^−5^ compared with five SNPs according to the null expectation (binomial test p=5·0×10^−13^; [appendix p 12, p 36](#sec1){ref-type="sec"}). We checked for false positives that were attributable to population stratification by adjusting our analyses with the first ten ancestry-informative principal components: our results did not change qualitatively ([appendix p 6, p 75](#sec1){ref-type="sec"}). New signals were not detected with HapMap-based imputation across the genome ([appendix p 3, p 6, pp 60--61](#sec1){ref-type="sec"}).

After large-scale replication, 71 (55%) of 129 signals taken forward had effects in the same direction as the discovery analysis on the basis of which they had been prioritised ([appendix pp 76--81](#sec1){ref-type="sec"}). All 26 SNPs selected for further follow-up had effects in the same direction (binomial p=2·98×10^−8^). Five of 26 loci had genome-wide significance (p=5·0×10^−8^) and three were very close to this ([table 2](#tbl2){ref-type="table"}). Effect size estimates for seven of eight loci were lower in the replication analysis than in the discovery analysis ([table 2](#tbl2){ref-type="table"}), with the exception of one signal (*ASTN2*).

The most significant signal was on chromosome 3 and was followed up by two SNPs in perfect linkage disequilibrium (LD) with each other: rs11177 (allele A; [figure A](#fig1){ref-type="fig"}), a missense polymorphism within exon three of *GNL3*, coding for nucleostemin, and rs6976 (allele T; [table 2](#tbl2){ref-type="table"}), situated in the 3′ untranslated region (UTR) of the *GLT8D1* gene. It was the only genome-wide significant signal in the discovery GWAS before replication ([table 2](#tbl2){ref-type="table"}; [appendix p 99](#sec1){ref-type="sec"}) for all osteoarthritis and TJR strata (with stronger evidence for association in the TJR strata).

All the remaining four genome-wide significant signals emanated from hip-specific strata ([table 2](#tbl2){ref-type="table"}): rs4836732 (allele C; female total hip replacement \[THR\]) located within intron 18 of the *ASTN2* gene ([figure B](#fig1){ref-type="fig"}; [table 2](#tbl2){ref-type="table"}); rs9350591 (allele T; hip osteoarthritis) located 38 kb upstream of *FILIP1* and 70 kb upstream of *SENP6* ([figure C](#fig1){ref-type="fig"}; [table 2](#tbl2){ref-type="table"}); rs10492367 (allele T; hip osteoarthritis) 59 kb downstream of *KLHDC5* and 96 kb downstream of *PTHLH* ([figure D](#fig1){ref-type="fig"}; [table 2](#tbl2){ref-type="table"}); and rs835487 (allele G; THR) located within intron two of *CHST11* ([figure E](#fig1){ref-type="fig"}; [table 2](#tbl2){ref-type="table"}).

Three additional signals lacked genome-wide significance and therefore need to be interpreted with caution. Rs12107036 was associated with osteoarthritis in women with total knee replacement (TKR; allele G) and is located within intron 12 of *TP63* ([appendix p 70](#sec1){ref-type="sec"}; [table 2](#tbl2){ref-type="table"}). Association with rs8044769 was strongest in the female osteoarthritis stratum (allele C), within intron 1 of *FTO* ([appendix p 71](#sec1){ref-type="sec"}; [table 2](#tbl2){ref-type="table"}). The final signal was seen in the male osteoarthritis stratum at rs10948172 (allele G), situated in the vicinity of the *SUPT3H* gene ([appendix p 72](#sec1){ref-type="sec"}; [table 2](#tbl2){ref-type="table"}).

We investigated the effect of the definition of disease phenotype on the strength of association of the replicating signals ([table 2](#tbl2){ref-type="table"}) by comparing the results of analyses of TJR-only cases (severe endpoint of disease) and all cases (TJR and radiography combined) for the stratum that had the lowest meta-analysis p value. We noted that, after large-scale replication, four signals (rs6976, rs4836732, rs835487, and rs12107036) were stronger in the TJR meta-analysis, one signal (rs9350591) was stronger in the meta-analysis of TJR and radiographic cases, and three signals (rs10492367, rs8044769, and rs10948172) were little changed ([appendix p 100](#sec1){ref-type="sec"}).

In the discovery set analyses of two types of controls---population-based controls unselected for osteoarthritis (n=11 009) and osteoarthritis-free controls (n=1828)---we compared the strength of association of the three previously established osteoarthritis loci ([appendix p 7, p 101](#sec1){ref-type="sec"}) and the eight replicating signals ([table 2](#tbl2){ref-type="table"}). We noted that one signal (*GDF5*) was stronger in the analysis of osteoarthritis-free controls, whereas the other ten were stronger or similar in the analyses of population-based controls ([appendix p 7, p 101, p 103](#sec1){ref-type="sec"}). In the meta-analysis of discovery and replication sets, effect size estimates for the replicating loci were the same or smaller for all variants except one (*CHST11*) when we used disease-free controls, and all signals were statistically stronger in the analyses of population-based controls ([appendix p 7, p 104](#sec1){ref-type="sec"}).

Because obesity is an established risk factor for osteoarthritis, we investigated whether any of the 129 prioritised signals were attenuated after adjustment for body-mass index (BMI) with arcOGEN cases and disease-free TwinsUK control data (BMI data were not available for the population-based controls). Two SNPs (rs11107957 and rs2626053) showed greater than 100-times increase in their p value (ie, became less significant) after adjustment for BMI ([appendix p 5, p 105](#sec1){ref-type="sec"}). Rs804476 in *FTO* was the only replicating signal to be attenuated after BMI adjustment in the discovery GWAS, but we cannot exclude the possibility that BMI adjustment might have had an effect on the other variants in the replication cohorts. However, in the discovery scan, the association p value at the four remaining loci that had genome-wide significance and the three signals just below this threshold were not affected by more than one order of magnitude after adjustment for BMI.

All the studied genes were expressed within osteoarthritic or control fracture neck-of-femur joint tissues ([appendix p 6, p 108](#sec1){ref-type="sec"}).

Immunohistochemical staining showed strong nucleolar expression of nucleostemin in cytospins of primary cultured chondrocytes from human articular cartilage derived from patients with osteoarthritis ([appendix p 69](#sec1){ref-type="sec"}), and a similar pattern of staining was seen in chondrocytes from frozen sections of osteoarthritic cartilage ([appendix p 69](#sec1){ref-type="sec"}). We measured levels of nucleostemin protein expression in cultured articular chondrocytes from five controls and five patients with osteoarthritis. Nucleostemin was barely detectable in cultured chondrocytes from controls but was clearly detectable in cultured chondrocytes from patients with osteoarthritis ([appendix p 69](#sec1){ref-type="sec"}). When nucleostemin expression was corrected for expression of the housekeeping gene β-actin, the upregulation of nucleostemin protein levels in osteoarthritis chondrocytes versus control chondrocytes was significant (p=0·003; [appendix p 69](#sec1){ref-type="sec"}).

Discussion {#cesec80}
==========

We have identified eight novel loci that are associated with the risk of developing osteoarthritis, five of which surpassed genome-wide significance and three that were just less than the threshold ([panel](#box1){ref-type="boxed-text"}). With the addition of previously established associations on chromosome 7q22, and in the *GDF5* and *MCF2L* genes,[@bib6; @bib7; @bib9; @bib11] the current total of osteoarthritis susceptibility loci in European populations is 11.

Our most significant finding was in a gene-rich region of chromosome 3p21·1. Rs6976 lies within the 3′ UTR of *GLT8D1* (glycosyltransferase 8 domain containing 1; [figure A](#fig1){ref-type="fig"}). Alterations in the expression of *GLT8D1* could affect the glycosylation of cartilage proteins. Rs11177, in perfect LD with rs6976, encodes a missense variant (Arg→Gln) in the third exon of *GNL3* (guanine nucleotide binding protein-like 3, or nucleostemin; [figure A](#fig1){ref-type="fig"}). *GNL3* is expressed in mesenchymal stem cells, from which chondrocytes are derived, and regulates the G1--S phase transition in stem cells.[@bib13; @bib14; @bib15] The function of *GNL3* in bone and cartilage is not known because mice homozygous for deletion of *GNL3* die on embryonic day 4.[@bib16] However, of interest is that nucleostemin protein levels were substantially increased in cultured chondrocytes from patients with osteoarthritis compared with controls, raising the possibility that this gene might be functionally important in the pathogenesis of osteoarthritis.

Rs4836732 lies within the *ASTN2* gene (astrotactin 2; [figure B](#fig1){ref-type="fig"}), which is highly expressed in the developing and adult brain. ASTN2 is a membrane protein that regulates surface levels of ASTN1 during neuronal migration.[@bib17] Rs9350591 lies between the *FILIP1* (filamin A interacting protein 1) and *SENP6* (sentrin specific peptidase 6) genes ([figure C](#fig1){ref-type="fig"}). *COL12A1* (collagen, type XII, alpha 1), the product of which is found in articular cartilage,[@bib18] lies at a distance of about 326 kb. Rs10492367 is located between the *KLHDC5* (Kelch domain containing 5) and *PTHLH* (parathyroid hormone-like hormone) genes ([figure D](#fig1){ref-type="fig"}). Parathyroid hormone-related protein (PTHrP) regulates endochondral bone development. Results from studies of Pthrp--/-- mice showed that animals who survived gestation had accelerated differentiation of chondrocytes in bone.[@bib19]

Rs835487 is located in the *CHST11* (carbohydrate sulfotransferase 11) gene ([figure E](#fig1){ref-type="fig"}), which encodes a Golgi enzyme that catalyses the transfer of sulphate groups to the 4-O position of chondroitin and dermatan sulphate, important components of cartilage proteoglycans.[@bib20] *CHST11* has a role in skeletal development, signalling pathways, and cancer progression.[@bib21] It has substantially higher expression in osteoarthritic cartilage than in normal articular cartilage[@bib22] and mice that are null for this gene have a disorganised growth plate, accelerated chondrocyte differentiation, altered patterns of signalling with transforming growth factor β and bone morphogenetic protein, and a fibrillated cartilage extracellular matrix that is characteristic of osteoarthritic cartilage.[@bib23] Chondroitin sulfate is used as a symptomatic, slow-acting drug for osteoarthritis, recommended by the latest Osteoarthritis Research Society International treatment guidelines, but evidence for its effectiveness remains controversial.[@bib24]

Rs12107036 lies within intron 12 of the *TP63* gene (encoding tumour protein p63; [appendix p 70](#sec1){ref-type="sec"}). p63 null mice have serious defects in their limb, craniofacial, and epithelial development.[@bib25; @bib26] Rs8044769 lies within *FTO* ([appendix p 71](#sec1){ref-type="sec"}), a well established locus that is associated with fat mass and obesity[@bib27] and is in partial LD (*r^2^*\>0·6) with the reported index BMI-associated SNPs. This signal was attenuated after adjustment for BMI, suggesting that the *FTO* gene exerts its effect on osteoarthritis through obesity. Rs10948172 occurs between *CDC5L* (CDC5 cell division cycle 5-like) and *SUPT3H* genes (suppressor of Ty3 homologue; [appendix p 72](#sec1){ref-type="sec"}). At a distance of 500 kb, but possibly containing SNPs correlated with rs10948172, is the *RUNX2* (runt-related transcription factor 2) gene, which encodes a protein that is essential for osteoblast differentiation[@bib28] and skeletal morphogenesis.[@bib29] *RUNX2* was identified in peripheral blood expression profiles as a possible biomarker for bone metabolism in arthritis.[@bib30]

The results of our study draw attention to three important issues with respect to design and analysis that are of relevance to GWAS investigations of complex disease: definition of significant association in view of several correlated stratified analyses; effect of phenotype homogeneity and misclassification; and allowing for power constraints when seeking replication of previously identified loci. First, we analysed several specific non-independent phenotypes in addition to the main analysis of all osteoarthritis cases versus controls so as to increase power to detect signals specific for joint, sex, or disease severity. Compelling evidence suggests that joint-specific genetic factors play a part in the pathogenesis of osteoarthritis[@bib31] and that the familial concordance for hip and knee osteoarthritis is greater in surgically defined than in radiographically defined disease.[@bib32; @bib33; @bib34] The results of these reports, in addition to the significant differences reported in the prevalence of osteoarthritis between skeletal sites, the sexes, and radiographic versus symptomatic disease,[@bib35] underpin our decision to stratify our data by site of osteoarthritis (hip or knee), sex, sex with site, and the two modes of osteoarthritis definition (radiographic and joint replacement) that we have used. That most of the loci we have identified are associated with osteoarthritis at a particular joint site provides genetic evidence that the aetiopathogenesis of osteoarthritis is not uniform, but that joint-specific risk factors are in operation. A conservative Bonferroni correction, assuming the independence of these highly correlated specific phenotypes, would artificially move the p-value threshold of declaring genome-wide significant association to 2·08×10^−9^.[@bib36] In this work, we draw attention to eight novel associations with osteoarthritis based on a combination of statistical evidence of association, corroborative evidence from large-scale replication, and biological insights afforded by the replicating loci that we noted (eg, *PTHLH* and *CHST11*, both excellent biological candidates, would not have surpassed the more stringent threshold).

Second, we accrue evidence that, in general, analyses of patients ascertained by the more stringent criterion of arthroplasty have power advantages over those including radiographically diagnosed cases, emphasising the value of patient phenotype homogeneity ([appendix p 100](#sec1){ref-type="sec"}). All eight loci reported in this study were prioritised on the basis of analyses of osteoarthritis-status-agnostic controls, indicating that the large increase in sample size afforded by the use of population-based controls might have power advantages despite potential misclassification ([appendix pp 101--04](#sec1){ref-type="sec"}).

Third, we assessed evidence for association at the three previously reported osteoarthritis loci in our discovery GWAS. We detected signals with p=0·002 to p=6×10^−4^ for the chromosome 7 and *MCF2L* loci, but little evidence for association at *GDF5*. These results are in keeping with findings in other complex disease discovery GWAS[@bib37] and can be ascribed to a combination of power, stochastic variation in allele frequency estimates, and the absence of the index variant from the genotyping platform ([appendix p 7, p 101](#sec1){ref-type="sec"}).

We have studied common variants and therefore the findings of our report cannot be used to estimate the effect that rarer variants might have on causing osteoarthritis. Further, although our discovery sample size of 7410 cases is the largest yet used for osteoarthritis, the sample was stratified; an analysis of larger stratified subsets might show additional associated loci. In our study, we focused on Europeans and it will be of great interest to assess whether these loci have global relevance to osteoarthritis risk through similar studies of non-European cohorts with osteoarthritis.

All eight identified loci are represented by common SNPs (minor allelic frequency 0·11--0·50) and have small effect sizes (allelic ORs from 1·11 to 1·21). In keeping with other common complex trait studies, these findings indicate that common SNPs with large effect sizes are not likely to have a role in the pathogenesis of osteoarthritis. Association at the index SNPs reported here does not imply causality. Functional studies will be necessary to pinpoint the precise functional variants. The eight signals identified in this study have a combined sibling recurrence risk (λs) estimate of 1·028 and account for only a small fraction of familial clustering of osteoarthritis. This outcome leads us to advocate larger-scale sample sizes, typically achieved through GWAS meta-analysis efforts in complex traits. The arcOGEN GWAS is the largest study of osteoarthritis genetics so far and has sufficient power to detect slight effects at common loci at the genome-wide significance level (eg, 80% power to detect an allele with frequency 0·35 and allelic OR of 1·15). We have established novel loci represented by common SNPs that confer a slight risk for osteoarthritis and are associated with the clinically important phenotype of TJR. These results provide a basis for functional studies to identify the underlying causative variants, biological networks, and molecular cause of osteoarthritis.
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![Regional association plots of replicating signals\
Case--control association results (--log~10~ \[p value\]) for genotyped SNPs in the discovery set are plotted against genomic position (National Center for Biotechnology Information build 36) for the stratum in which the most significant meta-analysis p value occurred. The index SNP is denoted by a purple diamond in the discovery set and by a purple square in the final meta-analysis. The circles indicate association results of genotyped SNPs in the region; the colour reflects the correlation coefficient (*r*^2^) of each genotyped SNP with the index SNP estimated with the CEU HapMap II panel. Estimated recombination rates (in cM/Mb) are plotted in red. The region shown in the plots extends to either 500 kb upstream and downstream of the index SNP or until the next recombination hotspot if this lies further than a distance of 500 kb. (A) Chromosome 3 signal centred on rs6976 in total joint replacement. (B) Chromosome 9 signal centred on rs4836732 in female total hip replacement. (C) Chromosome 6 signal centred on rs9350591 in hip osteoarthritis. (D) Chromosome 12 signal centred on rs10492367 in hip osteoarthritis. (E) Chromosome 12 signal centred on rs835487 in total hip replacement. SNP=single nucleotide polymorphism. CEU=Utah residents with ancestry from northern and western Europe.](gr1){#fig1}

###### 

Characteristics of study populations

                   **Study description**   **Country of origin**   **Number of SNPs**   **Cases**   **Controls**   **Effective sample size**                                                                                                                                        
  ---------------- ----------------------- ----------------------- -------------------- ----------- -------------- --------------------------- -------------- -------------- -------------- ------------- ----------------------------------------------- -------- ---------------- --------
  arcOGEN          Discovery               UK                      485 491              7410        4476 (60·4%)   1606 (21·7%)                5804 (78·3%)   3266 (44·1%)   3498 (47·2%)   646 (8·7%)    Population[\*](#tbl1fn1){ref-type="table-fn"}   11 009   5515 (50·1%)     17 716
  arcOGEN          Discovery               UK                      532 234              4476        4476 (100%)    1113 (24·9%)                3363 (75·1%)   1934 (43·2%)   2135 (47·7%)   407 (9·1%)    Osteoarthritis free                             1828     1828 (100%)      5192
  deCODE           In silico               Iceland                 128                  2031        1179 (58·1%)   0                           2031 (100%)    1269 (62·5%)   636 (31·3%)    126 (6·2%)    Osteoarthritis free                             31 487   17 209 (54·7%)   3055
  EGCUT            In silico               Estonia                 80                   213         159 (74·6%)    NA                          NA             64 (30·0%)     123 (57·7%)    26 (12·2%)    Population                                      2531     1426 (56·3%)     786
  GARP             In silico               Netherlands             128                  215         170 (79·1%)    169 (78·6%)                 46 (21·4%)     67 (31·2%)     109 (50·7%)    39 (18·1%)    Population                                      1670     925 (55·4%)      762
  RSI              In silico               Netherlands             129                  1950        1353 (69·4%)   1628 (83·5%)                322 (16·5%)    458 (23·5%)    1179 (60·5%)   313 (16·1%)   KL\<2                                           3243     1642 (50·6%)     4871
  RSII             In silico               Netherlands             129                  485         306 (63·1%)    398 (82·1%)                 87 (17·9%)     116 (23·9%)    326 (67·2%)    43 (8·9%)     KL\<2                                           1460     752 (51·5%)      1456
  TwinsUK          In silico               UK                      129                  170         170 (100%)     170 (100%)                  0              57 (33·5%)     102 (60·0%)    11 (6·5%)     KL\<2                                           228      228 (100%)       390
  UK replication   De novo                 UK                      24                   2409        1453 (60·3%)   392 (16·3%)                 2017 (83·7%)   1032 (42·8%)   1170 (48·6%)   207 (8·6%)    Population                                      2319     334 (14·4%)      4726

Data are number (%), unless otherwise indicated. SNP=single nucleotide polymorphism. arcOGEN=Arthritis Research UK Osteoarthritis Genetics. EGCUT=Estonian Genome Centre of University of Tartu. NA=not available. GARP=Genetics OsteoArthritis and Progression. RS=Rotterdam study. KL=Kellgren-Lawrence score.

Drawn from the general population without consideration of their osteoarthritis status.

###### 

Association summary statistics for the eight replicating signals

                                                **Chromosome**   **Position**   **Nearest gene(s)**   **Effect allele**   **Stratum**                             **Discovery**   **Replication**     **Discovery and replication**   **Discovery and replication for analysis of all cases of osteoarthritis**                                                                         
  --------------------------------------------- ---------------- -------------- --------------------- ------------------- --------------------------------------- --------------- ------------------- ------------------------------- --------------------------------------------------------------------------- -------------- ------------------- -------------- ------------------- --------------
  rs6976[\*](#tbl2fn1){ref-type="table-fn"}     3                52703844       *GLT8D1*              T                   TJR                                     0·37            1·16 (1·11--1·22)   2·27×10^−10^                    1·07 (1·02--1·13)                                                           7·79×10^−03^   1·12 (1·08--1·16)   7·24×10^−11^   1·09 (1·06--1·12)   6·56×10^−09^
  rs11177[\*](#tbl2fn1){ref-type="table-fn"}    3                52696345       *GNL3*                A                   TJR                                     0·38            1·16 (1·11--1·22)   2·12×10^−10^                    1·07 (1·02--1·13)                                                           7·70×10^−03^   1·12 (1·08--1·16)   1·25×10^−10^   1·09 (1·06--1·12)   5·13×10^−09^
  rs4836732                                     9                118306516      *ASTN2*               C                   THR--female                             0·47            1·19 (1·10--1·28)   1·19×10^−05^                    1·23 (1·12--1·34)                                                           9·54×10^−06^   1·20 (1·13--1·27)   6·11×10^−10^   1·04 (1·01--1·07)   1·56×10^−02^
  rs9350591                                     6                76298247       *FILIP1*; *SENP6*     T                   Hip[†](#tbl2fn2){ref-type="table-fn"}   0·11            1·20 (1·11--1·30)   2·49×10^−06^                    1·16 (1·07--1·25)                                                           1·64×10^−04^   1·18 (1·12--1·25)   2·42×10^−09^   1·09 (1·04--1·13)   2·78×10^−04^
  rs10492367                                    12               27906237       *KLHDC5*; *PTHLH*     T                   Hip                                     0·19            1·18 (1·11--1·27)   1·20×10^−06^                    1·11 (1·04--1·18)                                                           1·18×10^−03^   1·14 (1·09--1·20)   1·48×10^−08^   1·06 (1·03--1·10)   9·02×10^−04^
  rs835487                                      12               103584897      *CHST11*              G                   THR                                     0·34            1·15 (1·08--1·22)   3·26×10^−06^                    1·11 (1·04--1·19)                                                           9·32×10^−04^   1·13 (1·09--1·18)   1·64×10^−08^   1·05 (1·02--1·08)   6·22×10^−04^
  rs12107036                                    3                191082854      *TP63*                G                   TKR--female                             0·52            1·23 (1·13--1·35)   3·03×10^−06^                    1·17 (1·05--1·30)                                                           4·73×10^−03^   1·21 (1·13--1·29)   6·71×10^−08^   1·05 (1·02--1·08)   2·15×10^−03^
  rs8044769[‡](#tbl2fn3){ref-type="table-fn"}   16               52396636       *FTO*                 C                   Female                                  0·5             1·17 (1·10--1·23)   5·98×10^−08^                    1·06 (1·01--1·12)                                                           2·01×10^−02^   1·11 (1·07--1·15)   6·85×10^−08^   1·07 (1·04--1·10)   3·56×10^−06^
  rs10948172                                    6                44885669       *SUPT3H*; *CDC5L*     G                   Male                                    0·29            1·17 (1·10--1·26)   5·02×10^−06^                    1·11 (1·04--1·19)                                                           2·48×10^−03^   1·14 (1·09--1·20)   7·92×10^−08^   1·08 (1·05--1·12)   6·14×10^−07^

The details of the individual discovery and replication results of analyses of all cases of osteoarthritis are shown in the [appendix p 99](#sec1){ref-type="sec"}. TJR=total joint replacement. THR=total hip replacement. TKR=total knee replacement. arcOGEN=Arthritis Research UK Osteoarthritis Genetics.

Represent the same signal, *r*^2^=1; both were prioritised and showed similar p values and effect sizes before and after replication.

Analyses in which a subset of samples with osteoarthritis at the hip and knee are also included in the arcOGEN discovery set and in the UK replication set.

This signal was attenuated after adjustment for body-mass index, suggesting that the *FTO* locus exerts its effect on osteoarthritis through obesity.

###### Research in context

**Systematic review**

We searched PubMed for articles in English with a combination of the terms "osteoarthritis" and "genetic" to identify reports of loci encoding susceptibility for osteoarthritis. We then focused on those in which genetic associations had been identified with a compelling level of significance (p≤5×10^−8^) and with replication. This gave three loci: *GDF5*, 7q22, and *MCF2L*. These formed the basis by which we put our GWAS results into context. In our search we also took advantage of the extensive knowledge of several of the arcOGEN investigators who have published many reviews about the genetics of osteoarthritis.

**Interpretation**

We identified eight novel genetic risk loci for osteoarthritis. Two are close to functional candidate genes that suggest clinical implications for osteoarthritis. *CHST11* codes for an enzyme that modulates cartilage proteoglycan, with proteoglycan modulation being an active area of osteoarthritis therapeutic development; nutraceutical compounds, such as chondroitin sulfate, have been extensively studied. Although the evidence of efficacy of such compounds in relieving signs and symptoms of osteoarthritis is weak, our results suggest that alternate therapeutic approaches acting on this same pathway could be clinically beneficial. Novel anabolic treatments for osteoporosis have been developed with peptide fragments based on parathyroid hormone, and our results suggest that investigating these compounds in the treatment of osteoarthritis, or assessing endpoints of osteoarthritis in previous clinical trials of parathyroid hormone, would now be sensible. Furthermore, the association with *FTO* draws attention to the interplay between bodyweight and osteoarthritis, and emphasises existing clinical advice that loss of excess bodyweight is a clinical recommendation for symptom relief and avoidance of osteoarthritis. Our demonstration that osteoarthritis risk loci are on the whole specific to either the hip or the knee informs the clinician that the pathophysiological process of this chronic disease is likely to have joint-specific components that need to be borne in mind when developing treatment regimens.

[^1]: Members listed at end of paper
